145 related articles for article (PubMed ID: 33325621)
1. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
[TBL] [Abstract][Full Text] [Related]
2. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
3. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
[TBL] [Abstract][Full Text] [Related]
4. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
Zhuang L; Boriboonnangkul P; Wang S; Yuan S
Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
[TBL] [Abstract][Full Text] [Related]
5. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
[TBL] [Abstract][Full Text] [Related]
6. First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.
Bekadja MA; Mansour B; Ouldjeriouat H; Entasoltan B; Bouchama S; Charef L; Amani K; Hakiki N; Bouamama F; Osmani S; Brahimi M; Arabi A; Bouhass R; Yafour N
Transfus Apher Sci; 2021 Jun; 60(3):103070. PubMed ID: 33612450
[TBL] [Abstract][Full Text] [Related]
7. Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years.
Nakamura Y; Okubo M; Furuta Y; Tokida M; Ichikawa K; Ohsaka A
Transfus Apher Sci; 2019 Dec; 58(6):102664. PubMed ID: 31753774
[TBL] [Abstract][Full Text] [Related]
8. An innovation in stem cell harvesting: Heparin use.
Gul HG; Erkurt MA; Sarici A; Kuku I; Kaya E; Berber I; Merter M; Bicim S; Ozgul M
Transfus Apher Sci; 2021 Oct; 60(5):103240. PubMed ID: 34404617
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
11. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study.
Turunen A; Partanen A; Valtola J; Ropponen A; Siitonen T; Kuittinen O; Kuitunen H; Putkonen M; Sankelo M; Keskinen L; Savolainen ER; Pyörälä M; Kuittinen T; Silvennoinen R; Penttilä K; Sikiö A; Vasala K; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2020 Jul; 60(7):1519-1528. PubMed ID: 32333404
[TBL] [Abstract][Full Text] [Related]
12. A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.
Lin Y; Park Y; Khanal A; Campbell-Lee S; Liu L; Chen Z; Patel P; Vidanovic V; Sweiss K; Irene G; Peace D; Rondelli D; Mahmud N
Eur J Haematol; 2022 Dec; 109(6):711-718. PubMed ID: 36030395
[TBL] [Abstract][Full Text] [Related]
13. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
Gutiérrez-Aguirre CH; Alvarado-Navarro DM; Palomares-Leal A; Mejía-Jaramillo G; Salazar-Riojas R; León AG; Colunga-Pedraza PR; Sotomayor-Duque G; Jaime-Pérez JC; Cantú-Rodríguez OG; Del Carmen Tarín-Arzaga L; Flores-Jiménez JA; Gómez-Almaguer D
Transfusion; 2019 Dec; 59(12):3721-3726. PubMed ID: 31618456
[TBL] [Abstract][Full Text] [Related]
14. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.
Prakash VS; Malik PS; Sahoo RK; Pramanik R; Choudhary P; Varshney AN; Kumar L
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):44-51. PubMed ID: 34452863
[TBL] [Abstract][Full Text] [Related]
15. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
Kurnikova E; Trakhtman P; Pershin D; Ilyushina M; Khismatullina R; Maschan M; Novichkova G; Maschan A
J Clin Apher; 2021 Aug; 36(4):547-552. PubMed ID: 33682959
[TBL] [Abstract][Full Text] [Related]
18. A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
Bhunia N; Abu-Arja R; Stanek JR; Mehyar LS; Shaw PJ; Kang HJ; Stein J; O'Brien TA; Roberts CH; Lee AC; Loeb DM; Ozkaynak MF; Dalal JD; Strahlendorf C; Goyal RK; Shenoy SS; Rangarajan HG
Transfusion; 2021 Mar; 61(3):894-902. PubMed ID: 33475172
[TBL] [Abstract][Full Text] [Related]
19. Impact of Plerixafor Use at Different Peripheral Blood CD34
Shah EE; Young RP; Wong SW; Damon LE; Wolf JL; Shah ND; Leavitt AD; Loeffler P; Martin TG
Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375
[TBL] [Abstract][Full Text] [Related]
20. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
